Fluorescence lifetime imaging (FLIm) data were collected from 192 tissue margins across 31 newly diagnosed IDH-wildtype glioblastoma patients. An expert neuropathologist initially labeled these into seven tumor cellularity classes, which were then refined into three classes ('low', 'moderate', 'high') through confident learning (a method to identify and correct label errors).
The resulting classifier achieved 96% accuracy in the three-class task. SHAP analysis (a technique for interpreting model predictions) revealed distinct optical signatures for tumor infiltration, and identified both biological factors (gray matter composition) and acquisition-related factors (blood contamination) that affected prediction confidence.
Blinded re-evaluation of margins flagged by confident learning demonstrated intra-pathologist variability, showing that selective relabeling improved data reliability more than exhaustive review of all labels.
Summaries like this, every morning.
Pick your industry and the AI tools you use, and get news related to your work every day.
Free · 30 seconds with Google · unsubscribe anytimeWhat is AIToday? →
Ask AI anything about this article. The AI reads this article, earlier AIToday articles, and Wikipedia, and cites its sources. Q&As are published on this page for other readers too.
Merck has signed an AI-related deal, one of several pharma items in a news roundup that also covers China and…

Merck announced a research collaboration with Isomorphic Labs to discover small-molecule candidates against an…

Pfizer CSO Chris Boshoff said the company aims to cut first-in-human time from roughly four years to two, and…

Pearl aquaculture operations in Ehime are using underwater sensors and AI to address high water temperatures a…

At the Jefferies Global Healthcare Conference in London, Pfizer CEO Albert Bourla said Chinese biotech will be…

Healthcare stocks fell as UnitedHealth's shares dropped and Oracle pitched AI agents to the sector
